Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Mississippi for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Mississippi only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Mississippi (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Imad Bitar (NPI 1821267998)

Field	Value
Entity Type	Individual
Organization	Imad Bitar
Address	104 Millsaps Dr
City	Hattiesburg
State	MS
ZIP	39402
Taxonomy	Rheumatology Physician
NPI Enumerated	February 22, 2008

Payer Source	Total Paid
Medicare	$3M
Medicaid	$0

Key Findings

This provider’s revenue profile is effectively single‑payer: lifetime Medicare revenue is $3M and there is no Medicaid billing on file, so Medicare constitutes the practical entirety of billed public payer activity for this NPI. The NPI was enumerated on 2008-02-22 (~18 years ago), indicating a long-tenured presence in the market that likely supports established referral flows and operational capacity.

Revenue is concentrated in a small set of biologic drug codes: the precomputed top‑3 Medicare codes account for 55.1% of this provider’s total Medicare revenue, with the single largest code J0129 representing $771.8K (25.1%) of Medicare revenue. This level of concentration means a handful of injectable biologics drive the majority of publicly billed income.

The code mix—dominated by J0129, J9312, J0897 and supported by other J‑codes such as J3262, J1602, and J0717—points to a practice organized around administration and management of infused and injected biologic therapies consistent with rheumatology services and bone‑health treatments. The presence of multiple high‑volume biologic J‑codes suggests on‑site infusion or direct supervised administration is a core operational service line.

J0897 (denosumab) is an outlier: it generated $459K (14.9% of Medicare revenue) and the provider ranks #151 of 10057 nationally (98th percentile) with the label "extreme outlier, far above typical national volume." This indicates the provider administers denosumab at volumes far above most peers and likely serves as a regional nexus for this therapy.

By contrast, the leading immunomodulators J0129 (abatacept) at $771.8K and J9312 (rituximab) at $461.4K rank at the 92th and 91th percentiles respectively (#101 of 1221 and #28 of 317) and are characterized as "typical, unremarkable volume." These ranks indicate solid utilization of these agents but not national dominance—the provider is an active participant in these treatment lines without being an extreme national outlier.

Non‑drug codes show a mix of routine and elevated utilization: 99214 generated $91.5K (3.0%) and ranks #9236 of 479517 (98th percentile) labeled an "extreme outlier, far above typical national volume," implying unusually high office visit/E/M throughput relative to peers. Procedure and infusion administration codes such as 20611, 96413, 96401, and 96365 appear in the top 25, signaling capacity for joint procedures and both oncologic and non‑oncologic IV therapy administration in addition to biologic infusions.

Several additional codes are flagged as notably above typical national volume—specifically 96372 (98th percentile) and J3301 (97th percentile)—which supports the interpretation that this practice performs a high absolute volume of in‑office injections and therapeutic procedures. These elevated percentiles for injection and administration codes reinforce that frequent, procedure‑based encounters are a meaningful component of service delivery.

Operational and strategic implications stem from the combination of concentrated drug revenue and Medicare dependence: with $3M in Medicare receipts, no Medicaid activity, and 55.1% of Medicare revenue tied to the top three biologic codes, changes in reimbursement, utilization management, or drug supply affecting those agents could materially impact revenue. The long NPI tenure (2008-02-22 (~18 years ago)) suggests the practice has persistent infrastructure to deliver these services, but also places emphasis on maintaining payer contracting and operational resilience around biologic administration.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

35 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	22,700	$30	$771.8K
J9312	Injection, rituximab, 10 mg	7,210	$60	$461.4K
J0897	Injection, denosumab, 1 mg	25,500	$20	$459K
J3262	Injection, tocilizumab, 1 mg	80,400	$10	$402K
J1602	Injection, golimumab, 1 mg, for intravenous use	25,440	$10	$279.8K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	69,600	$1	$278.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,090	$80	$91.5K
J3111	Injection, romosozumab-aqqg, 1 mg	10,710	$10	$85.7K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	2,830	$30	$73.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	470	$80	$38.9K

Showing 1–10 of 35

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 35 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Mississippi Distribution

Imad Bitar — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Mississippi

Full comparison — all codes billed, vs. state median

35 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	1	10	8,840	$30	$367.2K
J3262	2	10	55,080	$1	$299.4K
J1602	4	10	18,250	$10	$265.7K
J9312	1	10	4,130	$60	$258.9K
J0717	2	10	36,000	$1	$144.1K
J3111	7	10	11,130	$10	$101.3K
J0897	3	110	3,030	$20	$95.7K
J1745	6	20	2,470	$30	$87.5K
96413	16	70	100	$80	$22.6K
99214	196	4,110	170	$70	$21.9K

Showing 1–10 of 35

Related Providers

Other providers that share a Tax Identification Number (TIN) with Imad Bitar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Hattiesburg Clinic PA	MS	Multi-Specialty Clinic/Center	$0	$59.5M
Hattiesburg Clinic PA	MS	Pediatrics Physician	$0	$10.9M
Hattiesburg Clinic PA	MS	Pediatrics Physician	$0	$7.9M
State Of Mississippi - University Of Mississippi Medical Center	MS	Critical Access Hospital	$0	$7.5M
Hattiesburg Clinic PA	MS	Ambulatory Surgical Clinic/Center	$4.5M	$2.4M
Lowery A. Woodall Outpatient Surgery Facility, LLC	MS	Ambulatory Surgical Clinic/Center	$446.4K	$6.1M
Hattiesburg Clinic PA	MS	Clinical Medical Laboratory	$2.2M	$3.3M
Hattiesburg Clinic, PA	MS	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$5.3M
Hattiesburg Clinic PA	MS	Obstetrics & Gynecology Physician	$0	$2.8M
Hattiesburg Clinic, PA	MS	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$2.5M

Nearby Providers

Other providers in the same ZIP code as Imad Bitar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Wesley Health System LLC	MS	General Acute Care Hospital	$0	$37.9M
Aaa Ambulance Service	MS	Land Ambulance	$5.2M	$20.1M
Wright Lauten	MS	Retina Specialist (Ophthalmology) Physician	$11.8M	$20.3K
Middleton & Belknap Pediatric Dentistry PLLC	MS	Pediatric Dentistry	$0	$11.3M
Metro Medical Supply Company LLC	MS	Durable Medical Equipment & Medical Supplies	$0	$10.2M
Hattiesburg Road Dental, P.C.	MS	General Practice Dentistry	$0	$10.1M
Wesley Physician Services LLC	MS	Family Medicine Physician	$0	$8.2M
Latonya Hailes	MS	Community Health Worker	$0	$8M
Oral & Maxillofacial Surgery Clinic Of South Misssissippi, P.A.	MS	Oral and Maxillofacial Surgery (Dentist)	$0	$7.4M
James Harris	MS	Pediatric Dentistry	$0	$7.2M

Imad Bitar — Billing Profile & Reimbursement Data

Sign up for Imad Bitar — Billing Profile & Reimbursement Data policy alerts

Imad Bitar — Billing Profile & Reimbursement Data

Sign up for Imad Bitar — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References